Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Major contract win

16 May 2014 12:25

RNS Number : 3595H
Venn Life Sciences Holdings PLC
16 May 2014
Β 

ο»Ώ

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Β 

Major contract win

Β 

Venn Life Sciences Signs Master Service Agreement for Multi-Country Study

Value is in excess of €3m covering 8 countries in Europe & North America over 18 months

Β 

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the securing of a multi-country multi-million euro clinical trials management agreement with a major European biotechnology company.

Β 

This multi-site agreement will run for over a year and a half, covering seven European countries as well as a number of US sites and is valued in excess of €3m. The clinical trial management programme is for an orphan drug in a rare acute disease area and is proceeding this month.

Β 

Over the past year Venn has increased its geographic footprint in Europe with new offices in the UK and Germany. Business development has been focused on key growth areas of drug and device development and on winning similar studies across Europe, with a solid pipeline of work for 2014 and 2015 now secured. Studies in rare diseases have increased significantly in recent years and Venn has invested in ensuring they have the critical multi-site agile service capabilities essential to conduct and manage trials efficiently in this sector.

Β 

Commenting, Venn CEO, Tony Richardson, said:

"We are hearing from many of our clients - in the key pharmaceutical, biotechnology and medical device sectors - of a growing need for a much more agile multi-country clinical trial management capability, especially in the still complex greater European region. Venn has invested heavily in 2013 in preparing the business for a step change in the size and complexity of contracts undertaken. This contract win, and our current pipeline, represent a significant endorsement of our investment strategy since IPO. We have now moved our business focus from small single country projects to larger multicentred projects and we expect to cement this progress with additional project wins in the coming months."

Β 

Enquiries:

Venn Life Sciences Holdings Plc

www.vennlifesciences.com

Tony Richardson, Chief Executive Officer

Tel: +353 154 99 341

Orla McGuinness, Marketing Manager

Tel: +33 (0)1 30 82 67 07

Zeus Capital (Nominated Adviser and Broker)

Ross Andrews/Andrew Jones (Corporate Finance)

Tel: 0161 831 1512

Dominic Wilson (Institutional Sales)

Tel: 020 7533 7727

Walbrook PR Ltd

Tel: 020 7933 8787 or venn@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

Β 

About Venn Life Sciences Limited:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management solutions and resourcing solutionsΒ to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK and Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - innoVenn - focused primarily on breakthrough development opportunities in Skin Science.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
CNTBBGDUSDBBGSL
Date   Source Headline
29th Jan 20204:43 pmRNSHolding(s) in Company
28th Jan 20207:00 amRNSCompulsory Acquisition of Remaining hVIVO Shares
27th Jan 20203:00 pmRNSHolding(s) in Company
23rd Jan 20207:00 amRNSUpdate on Placing
22nd Jan 20209:58 amRNSHolding(s) in Company
22nd Jan 20209:48 amRNSHolding(s) in Company
21st Jan 20202:07 pmRNSHolding(s) in Company
20th Jan 20204:28 pmRNSHolding(s) in Company
20th Jan 20208:00 amRNSEuronext Growth Dublin Notice
20th Jan 20207:59 amRNSEuronext Growth Dublin Cancellation Notice
20th Jan 20207:00 amRNSCompletion of Merger with hVIVO and Re-Admission
17th Jan 20207:00 amRNSOffer Wholly Unconditional
16th Jan 20202:00 pmRNSSchedule One Update - Open Orphan PLC
16th Jan 20202:00 pmRNSSchedule One Update
15th Jan 20205:30 pmRNSOpen Orphan
14th Jan 202011:12 amGNWForm 8.3 - Open Orphan plc
14th Jan 20207:00 amRNSSecond Closing of the Offer
13th Jan 20209:00 amRNSPrice Monitoring Extension
7th Jan 20202:12 pmRNSPublication and Posting of Rule 15 Proposals
6th Jan 20201:17 pmRNSResult of General Meeting
6th Jan 20208:00 amRNSSchedule One - Open Orphan plc
6th Jan 20208:00 amRNSSchedule One
6th Jan 20207:00 amRNSNew 3 Year Contract
2nd Jan 202011:55 amRNSForm 8.5 (EPT/NON-RI)
2nd Jan 202011:44 amRNSForm 8.3 - Open Orphan PLC
31st Dec 201911:00 amRNSForm 8.5 (EPT/NON-RI)
31st Dec 20197:00 amRNSOffer Update
30th Dec 201910:00 amRNSForm 8.5 (EPT/NON-RI)
23rd Dec 201910:00 amRNSForm 8.5 (EPT/RI) - Open Orphan plc
23rd Dec 20199:30 amRNSForm 8.5 (EPT/NON-RI)
20th Dec 20195:39 pmRNSForm 8.3 - Open Orphan Plc
19th Dec 20194:39 pmRNSForm 8.3 - Open Orphan plc
19th Dec 20191:36 pmRNSForm 8.3 - Open Orphan plc
19th Dec 201911:55 amRNSForm 8.5 (EPT/NON-RI)
18th Dec 201912:05 pmRNSForm 8.5 (EPT/NON-RI)
18th Dec 20197:00 amRNSNew Contract with SFA Therapeutics
17th Dec 20194:38 pmRNSForm 8.3 - Open Orphan Plc
17th Dec 20194:36 pmRNSForm 8 (OPD)
17th Dec 20192:06 pmRNSForm 8.3 - Open Orphan PLC
17th Dec 20192:06 pmRNSForm 8.3 - Open Orphan PLC
17th Dec 20192:04 pmRNSForm 8.3 - Open Orphan PLC
17th Dec 20192:04 pmRNSForm 8.3 - Open Orphan PLC
17th Dec 201911:55 amRNSForm 8.5 (EPT/NON-RI)
17th Dec 201910:19 amRNSForm 8 (OPD)
17th Dec 201910:19 amRNSForm 8 (OPD) (hVIVO plc)
16th Dec 20192:02 pmRNSForm 8 (OPD) Open Orphan plc
16th Dec 201911:55 amRNSForm 8.5 (EPT/NON-RI)
16th Dec 201910:26 amRNSForm 8.5 (EPT/RI) - Open Orphan plc
13th Dec 201911:44 amRNSForm 8.3 - Open Orphan PLC
13th Dec 20197:00 amRNSForm 8.3 - Open Orphan plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.